[1] |
Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin MicrobiloI Rev, 2002; 15, 716-46. doi: 10.1128/CMR.15.4.716-746.2002 |
[2] |
Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Ch, 2003; 47, 1958-62. doi: 10.1128/AAC.47.6.1958-1962.2003 |
[3] |
Heidarieh P, Mirsaeidi M, Hashemzadeh M, et al. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran. Microb Drug Resist, 2016; 22, 172-8. doi: 10.1089/mdr.2015.0134 |
[4] |
Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemot, 1999; 44, 393-5. doi: 10.1093/jac/44.3.393 |
[5] |
Swenson JM, Wallace RJ Jr, Silcox VA, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Ch, 1985; 28, 807-11. doi: 10.1128/AAC.28.6.807 |
[6] |
Santos A, Cremades R, Rodriguez JC, et al. Activity of various drugs alone or in combination against Mycobacterium fortuitum. J Infect Chemother, 2010; 16, 64-7. doi: 10.1007/s10156-009-0008-1 |
[7] |
Gole GV, Set R, Khan N, et al. Drug susceptibility testing of rapidly growing mycobacteria in extrapulmonary tuberculosis. Indian J Tuberc, 2016; 63, 119-22. doi: 10.1016/j.ijtb.2016.04.001 |
[8] |
Santos DR, Lourenco MC, Coelho FS, et al. Resistance profile of strains of Mycobacterium fortuitum isolated from clinical specimens. J Bras Pneumol, 2016; 42, 299-301. doi: 10.1590/s1806-37562016000000073 |
[9] |
Cao B, Qu JX, Yin YD, et al. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Respir J, 2015; DOI: 10. 1111/crj. 12379. |
[10] |
Bercovier H, Kafri O, Sela S. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem Biophys Res Commun, 1986; 136, 1136-41. doi: 10.1016/0006-291X(86)90452-3 |